Array ( [urn:ac.highwire.org:guest:identity] => Array ( [runtime-id] => urn:ac.highwire.org:guest:identity [type] => guest [service-id] => ajnr-ac.highwire.org [access-type] => Controlled [privilege] => Array ( [urn:ac.highwire.org:guest:privilege] => Array ( [runtime-id] => urn:ac.highwire.org:guest:privilege [type] => privilege-set [privilege-set] => GUEST ) ) [credentials] => Array ( [method] => guest ) ) ) 1naresh

Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)

Table 4: NI-RADS risk stratification guidelines^{^a}
Description Category Imaging Findings Management
Incomplete 0 New baseline study or unavailable previous imaging Previous imaging
No evidence of recurrence 1 Posttreatment changes without mass or abnormal FDG uptake Routine surveillance
Low suspicion (superficial) 2a Enhancement without FDG uptake or mild/moderate FDG uptake without a mass Direct visual inspection
Low suspicion (deep) 2b Enhancement without FDG uptake or mild/moderate FDG uptake without a mass Short imaging follow-up
High suspicion 3 New or enlarged mass or lymph node, enhancement, and intense FDG uptake Biopsy
Definitive recurrence 4 Pathologically proved or definite progression Clinical management
↵a The NI-RADS risk stratification guidelines grade head and neck tumor treatment response; adapted from Ref. 26.

Description	Category	Imaging Findings	Management
Incomplete	0	New baseline study or unavailable previous imaging	Previous imaging
No evidence of recurrence	1	Posttreatment changes without mass or abnormal FDG uptake	Routine surveillance
Low suspicion (superficial)	2a	Enhancement without FDG uptake or mild/moderate FDG uptake without a mass	Direct visual inspection
Low suspicion (deep)	2b	Enhancement without FDG uptake or mild/moderate FDG uptake without a mass	Short imaging follow-up
High suspicion	3	New or enlarged mass or lymph node, enhancement, and intense FDG uptake	Biopsy
Definitive recurrence	4	Pathologically proved or definite progression	Clinical management